Therapeutic targeting of trained immunity

Willem J.M. Mulder (Corresponding author), Jordi Ochando, Leo A.B. Joosten, Zahi A. Fayad, Mihai G. Netea (Corresponding author)

Research output: Contribution to journalReview articleAcademicpeer-review

11 Citations (Scopus)

Abstract

Immunotherapy is revolutionizing the treatment of diseases in which dysregulated immune responses have an important role. However, most of the immunotherapy strategies currently being developed engage the adaptive immune system. In the past decade, both myeloid (monocytes, macrophages and dendritic cells) and lymphoid (natural killer cells and innate lymphoid cells) cell populations of the innate immune system have been shown to display long-term changes in their functional programme through metabolic and epigenetic programming. Such reprogramming causes these cells to be either hyperresponsive or hyporesponsive, resulting in a changed immune response to secondary stimuli. This de facto innate immune memory, which has been termed ‘trained immunity’, provides a powerful ‘targeting framework’ to regulate the delicate balance of immune homeostasis, priming, training and tolerance. In this Opinion article, we set out our vision of how to target innate immune cells and regulate trained immunity to achieve long-term therapeutic benefits in a range of immune-related diseases. These include conditions characterized by excessive trained immunity, such as inflammatory and autoimmune disorders, allergies and cardiovascular disease and conditions driven by defective trained immunity, such as cancer and certain infections.

Original languageEnglish
Pages (from-to)553-566
Number of pages14
JournalNature Reviews Drug Discovery
Volume18
Issue number7
DOIs
Publication statusPublished - 9 Apr 2019

Fingerprint

Immunity
Immunotherapy
Immune System
Immune System Diseases
Myeloid Cells
Therapeutics
Epigenomics
Natural Killer Cells
Dendritic Cells
Autoimmune Diseases
Monocytes
Hypersensitivity
Homeostasis
Cardiovascular Diseases
Macrophages
Lymphocytes
Infection
Population
Neoplasms

Cite this

Mulder, W. J. M., Ochando, J., Joosten, L. A. B., Fayad, Z. A., & Netea, M. G. (2019). Therapeutic targeting of trained immunity. Nature Reviews Drug Discovery, 18(7), 553-566. https://doi.org/10.1038/s41573-019-0025-4
Mulder, Willem J.M. ; Ochando, Jordi ; Joosten, Leo A.B. ; Fayad, Zahi A. ; Netea, Mihai G. / Therapeutic targeting of trained immunity. In: Nature Reviews Drug Discovery. 2019 ; Vol. 18, No. 7. pp. 553-566.
@article{a0bb9d57d646491a918fe074770dbd75,
title = "Therapeutic targeting of trained immunity",
abstract = "Immunotherapy is revolutionizing the treatment of diseases in which dysregulated immune responses have an important role. However, most of the immunotherapy strategies currently being developed engage the adaptive immune system. In the past decade, both myeloid (monocytes, macrophages and dendritic cells) and lymphoid (natural killer cells and innate lymphoid cells) cell populations of the innate immune system have been shown to display long-term changes in their functional programme through metabolic and epigenetic programming. Such reprogramming causes these cells to be either hyperresponsive or hyporesponsive, resulting in a changed immune response to secondary stimuli. This de facto innate immune memory, which has been termed ‘trained immunity’, provides a powerful ‘targeting framework’ to regulate the delicate balance of immune homeostasis, priming, training and tolerance. In this Opinion article, we set out our vision of how to target innate immune cells and regulate trained immunity to achieve long-term therapeutic benefits in a range of immune-related diseases. These include conditions characterized by excessive trained immunity, such as inflammatory and autoimmune disorders, allergies and cardiovascular disease and conditions driven by defective trained immunity, such as cancer and certain infections.",
author = "Mulder, {Willem J.M.} and Jordi Ochando and Joosten, {Leo A.B.} and Fayad, {Zahi A.} and Netea, {Mihai G.}",
year = "2019",
month = "4",
day = "9",
doi = "10.1038/s41573-019-0025-4",
language = "English",
volume = "18",
pages = "553--566",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "7",

}

Mulder, WJM, Ochando, J, Joosten, LAB, Fayad, ZA & Netea, MG 2019, 'Therapeutic targeting of trained immunity', Nature Reviews Drug Discovery, vol. 18, no. 7, pp. 553-566. https://doi.org/10.1038/s41573-019-0025-4

Therapeutic targeting of trained immunity. / Mulder, Willem J.M. (Corresponding author); Ochando, Jordi; Joosten, Leo A.B.; Fayad, Zahi A.; Netea, Mihai G. (Corresponding author).

In: Nature Reviews Drug Discovery, Vol. 18, No. 7, 09.04.2019, p. 553-566.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Therapeutic targeting of trained immunity

AU - Mulder, Willem J.M.

AU - Ochando, Jordi

AU - Joosten, Leo A.B.

AU - Fayad, Zahi A.

AU - Netea, Mihai G.

PY - 2019/4/9

Y1 - 2019/4/9

N2 - Immunotherapy is revolutionizing the treatment of diseases in which dysregulated immune responses have an important role. However, most of the immunotherapy strategies currently being developed engage the adaptive immune system. In the past decade, both myeloid (monocytes, macrophages and dendritic cells) and lymphoid (natural killer cells and innate lymphoid cells) cell populations of the innate immune system have been shown to display long-term changes in their functional programme through metabolic and epigenetic programming. Such reprogramming causes these cells to be either hyperresponsive or hyporesponsive, resulting in a changed immune response to secondary stimuli. This de facto innate immune memory, which has been termed ‘trained immunity’, provides a powerful ‘targeting framework’ to regulate the delicate balance of immune homeostasis, priming, training and tolerance. In this Opinion article, we set out our vision of how to target innate immune cells and regulate trained immunity to achieve long-term therapeutic benefits in a range of immune-related diseases. These include conditions characterized by excessive trained immunity, such as inflammatory and autoimmune disorders, allergies and cardiovascular disease and conditions driven by defective trained immunity, such as cancer and certain infections.

AB - Immunotherapy is revolutionizing the treatment of diseases in which dysregulated immune responses have an important role. However, most of the immunotherapy strategies currently being developed engage the adaptive immune system. In the past decade, both myeloid (monocytes, macrophages and dendritic cells) and lymphoid (natural killer cells and innate lymphoid cells) cell populations of the innate immune system have been shown to display long-term changes in their functional programme through metabolic and epigenetic programming. Such reprogramming causes these cells to be either hyperresponsive or hyporesponsive, resulting in a changed immune response to secondary stimuli. This de facto innate immune memory, which has been termed ‘trained immunity’, provides a powerful ‘targeting framework’ to regulate the delicate balance of immune homeostasis, priming, training and tolerance. In this Opinion article, we set out our vision of how to target innate immune cells and regulate trained immunity to achieve long-term therapeutic benefits in a range of immune-related diseases. These include conditions characterized by excessive trained immunity, such as inflammatory and autoimmune disorders, allergies and cardiovascular disease and conditions driven by defective trained immunity, such as cancer and certain infections.

UR - http://www.scopus.com/inward/record.url?scp=85064222429&partnerID=8YFLogxK

U2 - 10.1038/s41573-019-0025-4

DO - 10.1038/s41573-019-0025-4

M3 - Review article

C2 - 30967658

AN - SCOPUS:85064222429

VL - 18

SP - 553

EP - 566

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 7

ER -